EP3720871A4 - Targeted immunotolerance - Google Patents

Targeted immunotolerance Download PDF

Info

Publication number
EP3720871A4
EP3720871A4 EP18887096.8A EP18887096A EP3720871A4 EP 3720871 A4 EP3720871 A4 EP 3720871A4 EP 18887096 A EP18887096 A EP 18887096A EP 3720871 A4 EP3720871 A4 EP 3720871A4
Authority
EP
European Patent Office
Prior art keywords
immunotolerance
targeted
targeted immunotolerance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18887096.8A
Other languages
German (de)
French (fr)
Other versions
EP3720871A1 (en
Inventor
Nathan HIGGINSON-SCOTT
Joanne L. Viney
Jyothsna Visweswaraiah
Erik Robert Sampson
Kevin Lewis Otipoby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pandion Operations Inc
Original Assignee
Pandion Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/034334 external-priority patent/WO2018217989A1/en
Priority claimed from US16/109,875 external-priority patent/US10174091B1/en
Application filed by Pandion Operations Inc filed Critical Pandion Operations Inc
Publication of EP3720871A1 publication Critical patent/EP3720871A1/en
Publication of EP3720871A4 publication Critical patent/EP3720871A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
EP18887096.8A 2017-12-06 2018-11-28 Targeted immunotolerance Pending EP3720871A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762595357P 2017-12-06 2017-12-06
US201762595348P 2017-12-06 2017-12-06
US201862675972P 2018-05-24 2018-05-24
PCT/US2018/034334 WO2018217989A1 (en) 2017-05-24 2018-05-24 Targeted immunotolerance
US15/988,311 US10676516B2 (en) 2017-05-24 2018-05-24 Targeted immunotolerance
US201862721644P 2018-08-23 2018-08-23
US16/109,875 US10174091B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
US16/109,897 US10174092B1 (en) 2017-12-06 2018-08-23 IL-2 muteins
PCT/US2018/062780 WO2019112852A1 (en) 2017-12-06 2018-11-28 Targeted immunotolerance

Publications (2)

Publication Number Publication Date
EP3720871A1 EP3720871A1 (en) 2020-10-14
EP3720871A4 true EP3720871A4 (en) 2021-09-15

Family

ID=66751175

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18887096.8A Pending EP3720871A4 (en) 2017-12-06 2018-11-28 Targeted immunotolerance

Country Status (3)

Country Link
EP (1) EP3720871A4 (en)
JP (1) JP2021505156A (en)
WO (1) WO2019112852A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
MX2020005208A (en) 2017-12-06 2020-08-20 Pandion Operations Inc Il-2 muteins and uses thereof.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. Madcam targeted immunotolerance
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE602005026779D1 (en) * 2004-01-09 2011-04-21 Pfizer ANTIBODIES AGAINST MAdCAM
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10174091B1 (en) * 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins

Also Published As

Publication number Publication date
WO2019112852A1 (en) 2019-06-13
JP2021505156A (en) 2021-02-18
EP3720871A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
EP3630163A4 (en) Targeted immunotolerance
EP3596108A4 (en) Targeted immunotolerance
EP3692489A4 (en) Quantumproof blockchain
EP3577127A4 (en) Targeted oligonucleotides
EP3645618A4 (en) Polyolefincomposition
EP3566431A4 (en) Multi-gimbal assembly
EP3690250A4 (en) Blower
EP3612249A4 (en) E-connected auto-injectors
EP3563482A4 (en) Counter-based sysref implementation
EP3720871A4 (en) Targeted immunotolerance
EP3645897A4 (en) Mount
EP3589248A4 (en) Cryotherapies
EP3876986A4 (en) Targeted immunotolerance
EP3639617A4 (en) Ran area id configuration
EP3684343A4 (en) Improved supraparticles
EP3688700A4 (en) Message-credentialed blockchains
EP3619920A4 (en) Metadata-free audio-object interactions
EP3574400A4 (en) Cyber-retro-reflector technology
EP3665276A4 (en) Improved endoinulinases
EP3596929A4 (en) Shoutcasting
EP3585947A4 (en) Embanking arrangement
EP3685644B8 (en) Rfid-carrel
EP3730143A4 (en) Omidenepag combination
EP3680136A4 (en) Airbag
EP3583153A4 (en) Biodegradable polyionenes

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VISWESWARAIAH, JYOTHSNA

Inventor name: VINEY, JOANNE L.

Inventor name: SAMPSON, ERIK ROBERT

Inventor name: HIGGINSON-SCOTT, NATHAN

Inventor name: OTIPOBY, KEVIN LEWIS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PANDION OPERATIONS, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210813

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20210809BHEP

Ipc: C07K 19/00 20060101ALI20210809BHEP

Ipc: C07K 14/55 20060101AFI20210809BHEP